Climb Bio
CLYM
75 hedge funds and large institutions have $63.4M invested in Climb Bio in 2025 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 23 reducing their positions, and 14 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 23
5% less funds holding
Funds holding: 79 → 75 (-4)
5.9% less ownership
Funds ownership: 82.87% → 76.97% (-5.9%)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
37% less capital invested
Capital invested by funds: $100M → $63.4M (-$36.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$2.96M |
| 2 |
CF
Cantor Fitzgerald
New York
|
+$2.19M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
+$1.62M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.62M |
| 5 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
+$898K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$5.72M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$4.7M |
| 3 |
BCM
Boxer Capital Management
San Diego,
California
|
-$3.99M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1.62M |
| 5 |
ABG
Ally Bridge Group
New York
|
-$1.37M |
CLYM Hedge Fund Activity: Q1 2025 in Review
75 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q1 2025, worth a combined $63.4M — down 37% from $100M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CLYM and 10 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 23 added.
The largest buyer was Citigroup, adding an estimated $2.96M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $5.72M sold.
- 75 institutional investors held Climb Bio (CLYM) as of Q1 2025, down from 79 in Q4 2024.
- Funds reported $63.4M of Climb Bio stock for Q1 2025, down 37% quarter-over-quarter.
- 10 funds opened new Climb Bio positions in Q1 2025 and 14 closed out, a net change of -4 holders.
- The largest Climb Bio buyer in Q1 2025 was Citigroup, an estimated $2.96M added.
- The largest Climb Bio seller in Q1 2025 was Janus Henderson Group, an estimated $5.72M sold.
Based on aggregated 13F filings for Q1 2025.